Preimplantation Genetic Testing Market size was over USD 1.97 billion in 2024 and is poised to reach USD 9.31 billion by the end of 2037, witnessing around 12.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of preimplantation genetic testing is assessed at USD 2.17 billion.
The growth of the preimplantation genetic testing market can be attributed to the rise in the number of new births born with congenital genetic disorders. The embryo is examined for a wide range of genetic problems during preimplantation genetic testing. According to the Centers for Disease Control and Prevention, the most frequent chromosomal disorder identified in the US is still Down syndrome. In the United States, roughly 6,000 newborns are born with Down syndrome every year. This indicates that roughly 1 in 700 infants have Down syndrome.
In addition to these, factors that are believed to fuel the preimplantation genetic testing market growth of preimplantation genetic testing include the rising cases of failed pregnancies, miscarriages, and others. Preimplantation genetic testing is typically utilized when women want to examine their embryos for issues that could result in another unsuccessful treatment after experiencing many miscarriages or failed IVF cycles. Embryos can also be examined for chromosomal issues using this method. Besides this, another application of preimplantation genetic testing, such as pre-implantation tissue typing is also helpful in testing for various blood disorders, including Wiscott-Aldrich Syndrome, and Sickle Cell Anaemia. PTT ensures the safe birth of a baby without any disease, moreover, it also predicts if the older sibling can successfully be treated with the stem cells of the new infant.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.6% |
|
Base Year Market Size (2024) |
USD 1.97 billion |
|
Forecast Year Market Size (2037) |
USD 9.31 billion |
|
Regional Scope |
|
Procedure Type (Preimplantation Genetic Diagnosis, Preimplantation Genetic Screening)
The global is segmented and analyzed for demand and supply by procedure type into preimplantation genetic diagnosis, and preimplantation genetic screening. Out of the types of procedures, the preimplantation genetic diagnosis segment is estimated to gain the largest preimplantation genetic testing market share in the year 2037. The growth of the segment can be attributed to the high efficiency of preimplantation genetic diagnosis. For high-genetic-risk couples with a known genetic condition, preimplantation genetic diagnosis (PGD) has been utilized successfully. Moreover, couples now have the chance to learn crucial genetic details about their embryos before starting a pregnancy owing to this revolutionary reproductive method. The hemoglobin illnesses thalassemia and sickle cell, the Fragile X syndrome, mental impairment condition, and muscular dystrophies are a few examples of single gene disorders for which couples frequently choose to use PGD. Preimplantation genetic diagnosis (PGD), also known as PGT-M, can be performed in conjunction with IVF to screen for more than 600 uncommon genetic disorders, including Cystic Fibrosis and premature Alzheimer's.
Application (HLA Typing, Aneuploidy Screening, IVF Prognosis)
The global preimplantation genetic testing market is also segmented and analyzed for demand and supply by application into HLA typing, aneuploidy screening, IVF prognosis, and others. Amongst these four applications of preimplantation genetic testing, the HLA typing segment is expected to garner a significant share in the year 2037. HLA typing examines certain immune system-related variables, and examination can determine whether a person is healthy enough to safely donate bone marrow, cord blood, or an organ to someone in need of a transplant. Moreover, organ donors who are terminally sick or recently passed away can also undergo HLA typing. The growth of the segment is primarily attributed to the rising demand for organ transplantation and the growing need for bone marrow. A bone marrow or umbilical cord blood transplant could save around 18,000 people between the ages of 0 and 74 every year, perhaps saving their lives.
Our in-depth analysis of the global preimplantation genetic testing market includes the following segments:
|
By Technology |
|
|
By Application |
|
|
By Procedure Type |
|
|
By Products & Services |
|
|
By End User |
|
North American Market Forecast
The market share of preimplantation genetic testing in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 38% by the end of 2037. The growth of the market can be attributed majorly to the rising cases of infertility in the region. According to Statistics Canada, in 2023, Canada's fertility rate is expected to be around 1.484 births per woman, a nearly 0.54% decrease from 2022. In Canada, the fertility rate fell by around 0.53% from 2021 to 2022, to around 1.492 births per woman. On the other hand, market growth in the region is also expected on the account of the rising need for bone marrow transplantation and organ transplantation. In the United States in 2020, more than 23,000 bone marrow or umbilical cord blood transplants were carried out.
Europe Market Forecast
The European preimplantation genetic testing market is estimated to be the second largest, registering a share of about 25% by the end of 2037. The growth of the market can be attributed majorly to the rising frequency of neo natal deaths. According to the Eurostat, in the EU, there were approximately 14 100 infant deaths in 2019. This translates to 3.4 newborn deaths for every 1000 live births, or the infant mortality rate. In addition to this, growing cases of congenital genetic deformity are also anticipated to boost the market growth in Europe. In the EU, there were approximately 14 100 infant deaths in 2019. This translates to 3.4 newborn deaths for every 1000 live births, or the infant mortality rate. Moreover, in Europe, the average age of first-time motherhood is also increasing which in turn pushing people to go for in-vitro fertilization in order to conceive.
APAC Market Statistics
Further, the preimplantation genetic testing market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increasing instances of stem cells, organ, and bone marrow transplants. Any sort of transplantation has become safer with the use of preimplantation genetic testing, that ensures if the donor is healthy enough to donate and if receiver is getting the donation from its perfect match. Around 2,000 stem cell transplants are performed in India each year, 80,000 to 1,00,000 transplants are needed each year to address the high incidence of blood malignancies and severe blood diseases. However, finding a compatible donor is quite challenging. Moreover, less than a million Indian bone marrow donors are listed on the registry.
Eurofins Genoma launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. Preimplantation genetic testing for aneuploidy (PGT-A) enables medical professionals to determine the chromosomal makeup of in vitro fertilized (IVF) embryos
LifeView powered by Genomic Prediction announces the partnership of Ovation Fertility with Genomic Prediction to approve the license for the LIfeView PGT Platform for genetic testing. Through this partnership, Ovation patients will have access to cutting-edge technologies and better clinical care.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?